Literature DB >> 24703738

[Epidemiology, clinical spectrum of ALS and differential diagnoses].

Philippe Couratier1, Benoît Marin2, Géraldine Lautrette3, Marie Nicol4, Pierre-Marie Preux2.   

Abstract

Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron disease in adults. Its incidence in France is estimated at 2.5 per 100,000 population and its prevalence between 5 and 8 per 100,000 inhabitants. Good prognostic factors are age of early onset, a longer time to diagnosis, initial damage to the spinal onset, early management of undernutrition and restrictive respiratory failure. The diagnosis of ALS is primarily clinical and is based on the evidence of involvement of the central motor neuron and peripheral neuron (NMP) in different territories or spinal or bulbar. The EMG confirms the achievement of NMP, shows the extension to clinically preserved areas and allows to exclude some differential diagnoses. The clinical spectrum of ALS is broad: conventional forms beginning brachial, lower limb or bulbar onsets, rarer forms to start breathing, pyramidal forms, forms with cognitive and behavioural impairment. In 5-10% of cases, ALS is familial. In 15% of cases, it is associated with frontotemporal degeneration rather than orbito-frontal type. The main differential diagnoses are guided by the clinic: combining pure motor neuropathy with or without conduction block, post-polio syndrome, cramp-fasciculation syndrome, myasthenia gravis, paraneoplastic syndromes, Sjögren syndrome, retroviral infections, some endocrine disorders, some metabolic diseases, genetic diseases (Kennedy and SMA) and inclusion body myositis.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24703738     DOI: 10.1016/j.lpm.2014.02.013

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  2 in total

1.  Minimizing the Diagnostic Delay in Amyotrophic Lateral Sclerosis: The Role of Nonneurologist Practitioners.

Authors:  Martin Matharan; Stéphane Mathis; Sarah Bonabaud; Louis Carla; Antoine Soulages; Gwendal Le Masson
Journal:  Neurol Res Int       Date:  2020-05-11

2.  GEMALS: A promising therapy for amyotrophic lateral sclerosis.

Authors:  Michel Geffard; Arturo Mangas; Denis Bedat; Rafael Coveñas
Journal:  Exp Ther Med       Date:  2018-02-14       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.